ENB-105 is under development for the treatment of inflammatory bowel disease and immune checkpoint inhibitor colitis (ICI-Colitis). It is being developed based on eSTEM systems biology platform.

ND02 is under clinical development by HK inno.N and currently in Phase II for Glaucoma. According to GlobalData, Phase II drugs for Glaucoma have a 39% phase transition success rate (PTSR) indication ...

In recent years, the oil and gas industry has progressed from using digital technologies for select use cases to making their ...

The surge in machinery patents is driven by the need for technological innovation to improve excavation processes.

Operational risks are also reduced due to a lesser need for human intervention in hazardous environments, which is a very ...

Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...

It’s become evident that a cloud-based IT portfolio brings organisations the greatest promise for providing the type of ...

The life insurance industry in South Korea will regain momentum in 2024 and 2025 after declining by 9.2% in 2023.

As inflation continues to squeeze household budgets across the Asia-Pacific (APAC) region, consumers are increasingly turning ...

In a release sent to Rigzone recently, GlobalData said the oil and gas industry has seen a dip in active jobs in 2024 but ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...